• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/26/26 4:18:46 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KLRA alert in real time by email
    8-K
    0002096997false00020969972026-05-262026-05-26

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 26, 2026

     

     

    Kailera Therapeutics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-43233

    99-3088927

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    180 Third Avenue, 4th Floor

     

    Waltham, Massachusetts

     

    02451

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 781 317-0290

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.00001 per share

     

    KLRA

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 26, 2026, Kailera Therapeutics, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended March 31, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit Number

     

    Description

    99.1

     

    Earnings Press Release dated May 26, 2026.

    104

     

    Cover Page Interactive Data File (embedded within the inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Kailera Therapeutics, Inc.

     

     

     

     

    Date:

    May 26, 2026

    By:

    /s/ Douglas Pagán

     

     

     

    Douglas Pagán
    Chief Financial Officer
     

     


    Get the next $KLRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KLRA

    DatePrice TargetRatingAnalyst
    5/12/2026$30.00Overweight
    Analyst
    5/12/2026Outperform
    William Blair
    5/12/2026$36.00Outperform
    Leerink Partners
    5/12/2026$57.00Buy
    TD Cowen
    5/12/2026Outperform
    Evercore ISI
    5/12/2026$48.00Buy
    Jefferies
    More analyst ratings

    $KLRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Kailera Therapeutics with a new price target

    Analyst initiated coverage of Kailera Therapeutics with a rating of Overweight and set a new price target of $30.00

    5/12/26 8:32:38 AM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Kailera Therapeutics

    William Blair initiated coverage of Kailera Therapeutics with a rating of Outperform

    5/12/26 8:32:38 AM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Kailera Therapeutics with a new price target

    Leerink Partners initiated coverage of Kailera Therapeutics with a rating of Outperform and set a new price target of $36.00

    5/12/26 8:32:17 AM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KLRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Tregoning Kathleen

    4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

    7/8/26 4:20:04 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Tregoning Kathleen

    3 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

    7/8/26 4:15:04 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Renaud Ronald C Jr exercised 38,094 shares at a strike of $5.25 (SEC Form 4)

    4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

    6/11/26 4:05:10 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KLRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

    In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial of KAI-7535 in obesity to further optimize KAI-7535's clinical profile for the treatment of obesityIn second Phase 3 trial in type 2 diabetes in China, HRS-7535 lowered HbA1c by an average of 1.50% to 1.68% across dosesLiver safety findings in both Phase 3 trials consistent with data generated to date; no liver safety signals observed WALTHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Kailera), a clinical-stage biotechnology company focused on elevating t

    7/7/26 7:00:00 AM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

    WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per

    6/29/26 7:30:00 AM ET
    $KLRA
    $CMPS
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

    Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweightAdditional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectivelyPhase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China

    6/5/26 7:32:00 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KLRA
    SEC Filings

    View All

    SEC Form 10-Q filed by Kailera Therapeutics Inc.

    10-Q - Kailera Therapeutics, Inc. (0002096997) (Filer)

    5/26/26 4:29:25 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kailera Therapeutics, Inc. (0002096997) (Filer)

    5/26/26 4:18:46 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by Kailera Therapeutics Inc.

    SCHEDULE 13D - Kailera Therapeutics, Inc. (0002096997) (Subject)

    4/23/26 8:01:50 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KLRA
    Leadership Updates

    Live Leadership Updates

    View All

    Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

    WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per

    6/29/26 7:30:00 AM ET
    $KLRA
    $CMPS
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care